Clinical trials: Respiratory Disorder
NSCLC (advanced Non-small Cell Lung Cancer)
Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function
This study will be conducted in subjects with moderate Hepatic Impairment, mild hepatic Impairment and normal hepatic function. The study will be conducted in two stages.
- Trial name
- NCT06823258
- Testing
- HS-10365
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Eosinophilic Asthma
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by…
- Trial name
- NCT01290887
- Testing
- Reslizumab
- Where
- 219 sites in United States, Argentina and 29 more
- Volunteers
- 1,052 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma, Rhinitis, Allergic, Perennial
Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
The primary objective of the current study is to investigate the safety and tolerability of BI 671800 HEA in healthy Chinese male volunteers following single oral administration, and healthy Japanese male volunteers following…
- Trial name
- NCT01216384
- Testing
- BI 671800
- Where
- South Korea
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)
This is a randomized, double-blind, placebo-controlled study of camostat mesilate in ambulatory patients with confirmed COVID-19 with at least one risk factor for severe illness.
- Trial name
- NCT04583592
- Testing
- Camostat Mesilate
- Where
- 21 sites in United States
- Volunteers
- 295 people
- Sponsor
- Sagent Pharmaceuticals Inc.
Pneumonia, Bacterial
A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella.
- Trial name
- NCT00111644
- Testing
- Ceftriaxone, beta-lactam
- Where
- 49 sites in United States, Argentina and 9 more
- Volunteers
- 302 people
- Sponsor
- Hoffmann-La Roche
Asthma
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
This study will be conducted to evaluate the effect of once daily treatment with fluticasone furoate (FF) on lower leg growth in pediatric subjects with persistent asthma by using knemometry.
- Trial name
- NCT02502734
- Testing
- Fluticasone furoate, Salbutamol
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell…
- Conditions
- Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05077709
- Testing
- IO102-IO103 in combination with pembrolizumab
- Where
- 21 sites in United States, Spain and 1 more
- Volunteers
- 63 people
- Sponsor
- IO Biotech
Refractory Chronic Cough
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- SOOTHE (NCT04678206)
- Testing
- BLU-5937
- Where
- 116 sites in United States, Canada and 5 more
- Volunteers
- 310 people
- Sponsor
- Bellus Health Inc. - a GSK company
Lung Cancer (Diagnosis)
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens for use in assessing new biomarkers for the detection of neoplasms of the lung.
- Trial name
- NCT03633006
- Testing
- Blood Sample Collection
- Where
- 83 sites in United States
- Volunteers
- 3,298 people
- Sponsor
- Exact Sciences Corporation
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
This trial in healthy subjects will assess PUR118's effect on attenuating ozone induced airway inflammation. This trial will establish the tolerability of PUR118 in healthy normal volunteers.
- Trial name
- NCT01690949
- Testing
- PUR118
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
COPD
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their…
- Trial name
- NCT01985334
- Testing
- Glycopyrronium, SABA, LABA
- Where
- 542 sites in Austria, Belgium and 21 more
- Volunteers
- 4,389 people
- Sponsor
- Novartis Pharmaceuticals
Sleep Apnea, Obstructive
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome
The primary objectives of the study are to determine the effectiveness of PROVIGIL treatment, compared to placebo treatment, in children and adolescents with excessive sleepiness (ES) associated with obstructive sleep…
- Trial name
- NCT00107809
- Testing
- Modafinil
- Where
- 64 sites in United States, Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Cephalon
Idiopathic Pulmonary Fibrosis (IPF)
Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
- Trial name
- IPF (NCT07728721)
- Testing
- HSK50042 dose 1, HSK50042 dose 2, HSK50042 dose 3
- Volunteers
- 175 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Extensive Stage Small Cell Lung Cancer
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
- Trial name
- DeLLphi-308 (NCT06598306)
- Testing
- Tarlatamab
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 220 people
- Sponsor
- Amgen
Non-small Cell Lung Cancer
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
To describe the T790M mutation status of patients with locally advanced/metastatic NSCLC who progressed on previous EGFR TKI treatment in a real-world setting.
- Trial name
- NCT03519958
- Testing
- Plasma-tissue testing
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer.
- Trial name
- NCT00073151
- Testing
- ABT-751
- Where
- 17 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abbott
Non Small Cell Lung Cancer (NSCLC)
Osimertinib Study in Indian Patients
This is a prospective, single-arm, multicenter, phase-IV study investigating the safety of osimertinib in Indian adult patients.
- Trial name
- NCT03853551
- Testing
- Osimertinib
- Where
- 7 sites in India
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Asthma
Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination
The purpose of this study is to determine the bioequivalence of fluticasone furoate (FF) inhalation powder (single strip configuration) compared with FF inhalation powder (two strip configuration) and compared with FF /…
- Trial name
- NCT01485445
- Testing
- Fluticasone Furoate (200mcg unit strength), Fluticasone Furoate/Vilanterol (200/25mcg unit strength)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.